Science Popularization: Does Getting the Hepatitis B Vaccine Mean You’re Protected for Life?

Release date:

2023-08-02

Author:

Source:


Abstract

The widespread use of the hepatitis B vaccine has significantly reduced the incidence of hepatitis B in China. However, we often hear people around us wondering: “Why did my child’s hepatitis B antibody levels disappear after a period of time following vaccination? Could it be that they received a fake vaccine?” To address this concern, we must first ask: “Are hepatitis B antibodies truly long-lasting?” The answer is no.

 

The widespread use of the hepatitis B vaccine has significantly reduced the incidence of hepatitis B in China. However, in everyday life, we often hear people around us wondering: “Why did my child’s hepatitis B antibody levels disappear after a period of time following vaccination? Could it be that they received a fake vaccine?”

Hepatitis B antibodies are not permanently effective.

To answer this question, we must first ask: “Do hepatitis B antibodies provide lifelong protection?” The answer is “No.” Before getting vaccinated, it’s advisable to consult your doctor, who can provide a scientifically sound response.

In fact, whether adults or children, at 0 1. After receiving three doses of the hepatitis B vaccine in June, more than 95% of individuals will develop sufficient antibodies within 1 to 2 months. Typically, antibody levels (antibody titers) peak between six months and one year; however, if there is no prolonged exposure to the hepatitis B antigen, antibody production will gradually decline and eventually wane, with a natural lifespan of approximately 4 to 5 years. Long-term follow-up studies of vaccinated populations have shown that, after five years, 50% to 60% of individuals may test seronegative for hepatitis B antibodies.

It is very necessary to test the five hepatitis B markers.

As mentioned above, antibodies do not provide lifelong protection; so how can we determine whether we have developed antibodies?

The best approach is, of course, to go to the hospital for a hepatitis B five-item test—commonly referred to as the “hepatitis B two-and-a-half” panel. The test report typically looks like this:

During testing, if a particular parameter falls outside the reference range, it is considered a positive result. Depending on which of the five parameters are positive, various combinations can arise; common result patterns include:                

 

Hepatitis B virus surface antigen

Hepatitis B virus surface antibody

Hepatitis B virus E Antigen

Hepatitis B virus E antibody

Hepatitis B virus core antibody

Analysis of Test Results

-

-

-

-

-

Never infected with hepatitis B

-

+

-

-

-

Individuals who have been vaccinated against hepatitis B or who have recovered from a hepatitis B infection are immune.

+

-

-

-

-

In the early stages of acute infection or in chronic hepatitis B surface antigen carriers, infectivity is low.

+

-

+

-

+

Commonly referred to as “big three positives,” this indicates acute or chronic hepatitis B and is highly contagious.

+

-

-

+

+

Commonly referred to as “small three yang,” this indicates either acute or chronic hepatitis B, with relatively low infectivity.

+

-

+

-

-

Commonly referred to as “big two positive,” this indicates either early-stage hepatitis B infection or an active phase of chronic hepatitis B, with high infectivity.

+

-

-

-

+

Acute hepatitis B infection or chronic hepatitis B carriers have low infectivity.

-

+

-

-

+

Recovered from hepatitis B virus infection and now immune.

-

-

-

+

+

Individuals who have previously been infected with the hepatitis B virus or are in the recovery phase of hepatitis B infection are essentially non‑infectious.

Immune memory cells play a crucial role.

If the antibodies have disappeared, does that mean we no longer have any immunity against the hepatitis B virus?

At this point, the differences between those who have and have not received the hepatitis B vaccine become apparent.

After vaccination, our bodies produce hepatitis B surface antibodies. Over time, most of these antibodies gradually disappear; however, certain immune cells in our bodies “remember” what the hepatitis B virus looks like. We refer to these cells as memory immune cells. When the hepatitis B virus re-enters our body, these memory immune cells rapidly proliferate and promptly generate more hepatitis B surface antibodies to neutralize the virus. This phenomenon is known as… Immune memory Immune memory plays a crucial role in protecting our bodies from hepatitis B virus infection after antibody levels have declined.

Booster vaccinations should not be overlooked.

Does immune memory exist, so that after completing a vaccination course we would never need to receive the hepatitis B vaccine again?

The answer is also no, because this type of immune memory does not persist indefinitely; over time, it gradually diminishes, necessitating booster vaccinations to maintain immunity. Such booster doses… We call it a needle vaccine. Booster immunization

Because the duration of immune memory varies from person to person, there is no universal consensus on the optimal timing for booster vaccinations. At present, in China it is generally believed that after receiving the hepatitis B vaccine… 5 About 8 years Booster immunization is necessary, because administering another dose of the hepatitis B vaccine at this stage will elicit sufficient antibody responses in more than 95% of individuals. In contrast, if vaccination is delayed until 10 years later, only about 80% or fewer people will develop adequate antibodies—meaning that at least 20% will have lost their protective immunity against the hepatitis B virus and become susceptible to infection. Studies have shown that children who received a booster dose of the hepatitis B vaccine between the ages of 5 and 7 had a significantly lower risk of hepatitis B infection between ages 10 and 16 compared with their peers who did not receive a booster.

(This article is authored by Li Huayu, who holds a master’s degree in epidemiology and health statistics and previously served at the Disease Prevention and Control Center of a unit under the General Equipment Department of the People’s Liberation Army.)

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09